December 1, 2022 4:37pm

No tunnel vision here, this analyst/journalist gets into the weeds of daily share pricing and root causes.

Pre-open Indications: 4 Hit and 2 Miss

News: Compass Therapeutics (CMPX +$0.49) the first patient has been dosed in the P1b study of CTX-471 in combination with KEYTRUDA®, Merck’s anti-PD-1 therapy, in patients with advanced solid tumors.

Why do I keep writing this blog/newsletter; to inform investors, what others won’t say or write

Your portfolio should be profiting from RMi’s analysis; subscription is coming, it’s not conscription but, an offer to join our collective of like-minded investors! 

 

If I have learned one thing as a former research analyst in a venture and public fund now a journalist; it is that your life and your bank account are largely tied to your knowledge of price movements and questioning pricing targets.

 

The Dow closed DOWN – 193.77 points (-0.56%), the S&P close DOWN -3.43 points (-0.08%) while the Nasdaq closed UP +14.45 points (+0.13%)

 

Henry’omics:

We need to understand the macro to comprehend the micro re “our” universe of cell and gene therapy companies …

Indexes opened mixed on Thursday after an inflation measure PCE (personal consumption index) watched by the Fed came in a little lighter than expected.

Yet the market failed to hold those gains as traders showed caution before the important Friday jobs report.

Economic Data Docket: The October Core Personal Consumption Expenditures Index rose 0.2%, below the consensus estimate of 0.3% collected from economists by Dow Jones. The 10-year Treasury yield decreased after the report and stock futures gained.

·         The U.S. added 200,000 jobs in November, down from 261,000 in the prior month, according to economists.

·         Outlays for construction projects fell 0.3% in October at a seasonally adjusted annual rate of $1.79 trillion,

 

Thursday’s … RegMed Investor’s (RMi) Pre-Open: “upside action, after a surge; there’s usually a purge. While Wednesday's action was encouraging, investors should await the market’s reaction to the PCE price index along with the November jobs report Friday, will help shape Fed rate hike expectations.” … https://www.regmedinvestors.com/articles/12724

 

RegMed/Stem/Cell and Gene Therapy’s 35 covered equities’ Advance/Decline (A/D) lines: what happened

  • Thursday’s advance/decline line opened negative at 12 up/ 21 down and 2 flats, stayed negative with 11 up/ 23 down and 1 flat at the mid-day, with a negative close of 8/24 and 3 flats.

 

Pre-open indication results: 4 Hit <Beam Therapeutics (BEAM -$0.36), Chinook Therapeutics (KDNY -$0.17), Intellia Therapeutics (NTLA -$5.66), Sage Therapeutics (SAGE -$0.10)> and 2 Miss < Prime Therapeutics (PRME -$0.69), Verve Therapeutics (VERV +$0.66)>

 

Key Metrics:

The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:

  • Thursday, the IBB was up +0.46% and the XBI was down -0.61%

The CBOE Volatility Index (VVIX: INDEX) tracked:

  • Thursday was down -0.67 points or -3.26% at 20.19.91

 

Closing Down (10 or 24):

  • Intellia Therapeutics (NTLA -$5.66 after Wednesday’s +$3.46 after Tuesday’s -$0.26 and Monday’s -$1.42),
  • Prime Therapeutics (PRME -$0.69 after Wednesday’s -$0.14, Tuesday’s -$0.11 and Monday’s -$3.27),
  • Verve Therapeutics (VERV -$0.49 after Wednesday’s +$1.49 and Tuesday’s -$0.10),
  • Ionis Pharmaceuticals (IONS -$0.59 after Wednesday’s +$2.03, Tuesday’s -$1.57 and Monday’s -$1.23),
  • Editas Medicine (EDIT -$0.54),
  • Biostage (OTCQB: BSTG -$0.50),
  • Fate Therapeutics (FATE +$0.48),
  • Crisper Therapeutics (CRSP -$0.45 after Wednesday’s +$1.91, Tuesday’s -$0.46 and Monday’s -$1.65),
  • Regenxbio (RGNX -$0.36 after Wednesday’s +$1.34, Tuesday’s -$0.13 and Monday’s -$0.08),
  • Beam Therapeutics (BEAM -$0.36 after Wednesday’s +$2.58 after Tuesday’s +$0.43 and Monday’s -$1.10),

Flat (3):

  • Solid Biosciences (SLDB)
  • Precigen (PGEN),
  • Brainstorm Cell Therapeutics (BCLI)

Closing Up (8 of 8):

  • Ultragenyx (RARE +$1.51),
  • BioLife Solutions (BLFS +$0.70),
  • Compass Therapeutics (CMPX +$0.49 after Wednesday’s -$0.14 and Tuesday’s +$0.19),
  • Vericel (VCEL +$0.22 after Wednesday’s +$1.62, Tuesday’s +$0.12 and Monday’s -$0.46),
  • Voyager Therapeutics (VYGR +$0.10),
  • AxoGen (AXGN +$0.08),
  • MiMedx (MDXG +$0.02),
  • Adverum Biotechnologies (ADVM +$0.0081 after Wednesday’s -$0.01),

 

Q4 – December

  • Thursday (12/1/22) closed negative with 8 incliner, 24 decliners and 3 flats

 

The BOTTOM LINE: I try to keep it simple … and short!

There are still reasons to be cautious about the current market. The sector got a punch to the sector’s share pricing’s gut.

Investors should be “playing” this market, but not for all the marbles.

Just 21 trading days remain in 2022.

At any given time, not many stocks are flashing buy signals, while shakeouts and sector rotations can make holding onto positions difficult.

Avrobio (AVRO closed down -$0.014 to $0.89) filed a S-3 for $250 million common stock, preferred stock, debt securities, warrants and unit offering within draft prospectus by Cowen as stock sinks while delisting continues? Just another “screw-job” of investors! < Read, SELL and Weep - see hyperlink below> Avrobio (AVRO) files S-3 (Registration Statement) for offering with draft prospectus by Cowen … https://investors.avrobio.com/node/9116/html

As I continually question, “The real question that should be asked is how many companies are at the end of sentiments …  leash?

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.